TY - JOUR
T1 - The influence of adverse effects on quality of life of survivors of gynecologic cancer
AU - Omichi, Chiaki
AU - Nakamura, Keiichiro
AU - Haraga, Junko
AU - Ida, Naoyuki
AU - Saijo, Masayuki
AU - Nishida, Takeshi
AU - Kusumoto, Tomoyuki
AU - Masuyama, Hisashi
N1 - Publisher Copyright:
© 2017 by IGCS and ESGO.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Objective The objective of this observational study was to investigate correlations between adverse effects (lower-extremity lymphedema [LEL], dysuria, and severe gastrointestinal symptoms) and quality of life (QOL) (physical well-being [PWB], social well-being, emotional well-being [EWB], and functional well-being) before treatment, at least 6 weeks after treatment (posttreatment1), and 3 or 6 months after treatment (posttreatment2) of patients with gynecologic cancer (GC). Methods From August 2012 to October 2016, questionnaire responses and clinical data of 75 patients with GC were collected and assessed by treatment received. The χ2 test was used to determine the significance of correlations. Results Participants with LEL had significantly poorer QOL than did those without it in the domains of PWB at posttreatment1 (P = 0.026) and EWB at posttreatment2 (P = 0.020). Moreover, patients with 2 adverse effects (LEL plus dysuria or severe gastrointestinal symptoms) had significantly poorer QOL than did those with no or single adverse effect in the domains of PWB at posttreatment1 and posttreatment2 (posttreatment1: P = 0.049, P = 0.001; posttreatment2: P = 0.002, P = 0.028) and poorer QOL compared with those with no adverse effect in the domain of EWB at posttreatment1 (P = 0.017). Conclusions Poorer QOL in emotional and physical domains is associated with adverse effects of treatment in patients with GC. It is important to consider the effects of radical therapy not only on survival but also on the QOL of survivors.
AB - Objective The objective of this observational study was to investigate correlations between adverse effects (lower-extremity lymphedema [LEL], dysuria, and severe gastrointestinal symptoms) and quality of life (QOL) (physical well-being [PWB], social well-being, emotional well-being [EWB], and functional well-being) before treatment, at least 6 weeks after treatment (posttreatment1), and 3 or 6 months after treatment (posttreatment2) of patients with gynecologic cancer (GC). Methods From August 2012 to October 2016, questionnaire responses and clinical data of 75 patients with GC were collected and assessed by treatment received. The χ2 test was used to determine the significance of correlations. Results Participants with LEL had significantly poorer QOL than did those without it in the domains of PWB at posttreatment1 (P = 0.026) and EWB at posttreatment2 (P = 0.020). Moreover, patients with 2 adverse effects (LEL plus dysuria or severe gastrointestinal symptoms) had significantly poorer QOL than did those with no or single adverse effect in the domains of PWB at posttreatment1 and posttreatment2 (posttreatment1: P = 0.049, P = 0.001; posttreatment2: P = 0.002, P = 0.028) and poorer QOL compared with those with no adverse effect in the domain of EWB at posttreatment1 (P = 0.017). Conclusions Poorer QOL in emotional and physical domains is associated with adverse effects of treatment in patients with GC. It is important to consider the effects of radical therapy not only on survival but also on the QOL of survivors.
KW - Functional assessment of cancer therapy -general
KW - Gynecologic cancer
KW - Lower-extremity lymphedema
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85032966902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032966902&partnerID=8YFLogxK
U2 - 10.1097/IGC.0000000000001125
DO - 10.1097/IGC.0000000000001125
M3 - Article
C2 - 28930808
AN - SCOPUS:85032966902
SN - 1048-891X
VL - 27
SP - 2014
EP - 2019
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 9
ER -